Showing 5311-5320 of 7518 results for "".
- PSORRO: Oral Roflumilast Linked with Weight Loss in Patients with Psoriasishttps://practicaldermatology.com/news/effects-of-oral-roflumilast-therapy-on-body-weight-and-cardiometabolic-parameters-in-patients-with-psoriasis-results-from-a-randomized-controlled-trial-psorro/2462256/Roflumilast was associated with a decrease in appetite and weight loss in patients with psoriasis, according to a new study in JAAD. "Recent evidence indicates that roflumilast holds a therapeutic potential in psoriasis, a chronic inflammatory disease linked to overweight/
- Dermavant to Present New ADORING Data from Phase 3 Trials of Vtama Cream for AD at 2024 AAD Annual Meetinghttps://practicaldermatology.com/news/dermavant-to-present-new-adoring-data-from-phase-3-trials-of-vtama-cream-for-ad-at-2024-aad-annual-meeting/2462258/Dermavant Sciences announced that new ADORING data, including treatment of patients with skin of color, from phase 3 trials of Vtama (tapinarof) cream 1% in adults and children 2 years of age and older with atopic dermatitis (AD), will be presented at the 2024 American Academy of Dermatology annu
- La Roche-Posay Launches New Dark Spot Serumhttps://practicaldermatology.com/news/la-roche-posay-launches-dark-spot-serum/2462254/La Roche-Posay, a subsidiary of L'oreal, recently announced the launch of its new a new serum corrector for dark spots, the Mela B3 Dark Spot Serum with MelasylTM + Nicinamide. According to the manufacturer, the launch was preceded by 18 years of research, as well as rese
- Nutrafol® Announces Expansion Into Skin with Daily Acne Supplementhttps://practicaldermatology.com/news/hair-health-leader-nutrafol-expands-into-skin/2462253/Hair health leader Nutrafol has announced an expansion into the skin space with the launch of its new product, Nutrafol Skin. According to the manufacturer, the first-of-its-kind once-daily supplement for women 18 years of age and older who experience mild to moderate acne. A
- Alvotech and Teva Announce US Approval of Simlandi, a Biosimilar to Humirahttps://practicaldermatology.com/news/alvotech-and-teva-announce-us-approval-of-simlandi-a-biosimilar-to-humira/2462250/Alvotech and Teva Pharmaceuticals announced the FDA approval of Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to blockbuster drug Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as&n
- Fear of Cancer Recurrence Elevated Among Survivors of Localized Cutaneous Melanoma: Analysishttps://practicaldermatology.com/news/lived-experiences-and-fear-of-cancer-recurrence-among-survivors-of-localized-cutaneous-melanoma/2462249/Patients who suffer from localized cutaneous melanoma report high levels of fear of cancer recurrence, according to a new analysis. Researchers investigating the psychological well-being and fear of cancer recurrence among survivors of localized cutaneous melanoma in the United States ev
- CD19 CAR T-Cell Transfer Therapy Shows Promise for Systemic Lupus Erythematosushttps://practicaldermatology.com/news/cd19-car-t-cell-transfer-therapy-and-systemic-lupus-erythematosus/2462248/Results from a recent analysis in the New England Journal of Medicine suggested a potentially effective approach for treating autoimmune diseases like systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis. The case series analysi
- Study Highlights Fatigue Experienced by Psoriasis Patientshttps://practicaldermatology.com/news/study-highlights-fatigue-experienced-in-psoriasis/2462247/A new analysis in the Journal of the American Academy of Dermatology sought to tease out drivers of fatigue in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Researchers for the study examined various factors contributing to fatigue in these individuals using
- Biofrontera Announces Restructuring of Supply Agreement, Reduces Ameluz Transfer Pricinghttps://practicaldermatology.com/news/biofrontera-inc-announces-private-placement-of-up-to-160-million-priced-at-market-per-nasdaq-rules/2462246/Biofrontera has announced a restructuring of agreements with its former parent company, Biofrontera AG, aimed at enhancing long-term profitability. As a result, the transfer price of its leading product, Ameluz, indicated for the treatment of actinic keratosis, will be slashed from 50% to 25% for
- FDA Approves First Medication to Treat Severe Frostbitehttps://practicaldermatology.com/news/fda-approves-first-medication-to-treat-severe-frostbite/2462244/The FDA has approved Eicos Sciences' Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. “This approval provides patients with the first-ever treatment option for severe frostbite,” Norman Stockbridge, MD, PhD